Posted on 30/03/2010 in Scientific Hologic has published data from a clinical trial of its diagnostic test for human papillomavirus (HPV) which demonstrates its real-world efficacy.
The company's Cervista HPV HR test is being trialled among 10,000 patients in an ongoing study comparing its performance to that of the alternative Hybrid Capture 2 (hc2) testing system.
Interim results from the study reveal that the two methods are clinically equivalent, with the Cervista system offering strong performance in terms of sensitivity and specificity.
Dr Edward Evantash, medical director and vice-president of medical affairs at Hologic, added that its test offers further advantages such as a lower required sample size and a control to guard against false negatives.
He said: "Through both Cervista and our ThinPrep Pap Test, we are committed to continuing to advance the science and practice of preventing cervical cancer."
Last month, the company published its results for the first quarter of the 2010 fiscal year, during which it was able to exceed its guidance in terms of both earnings and revenue.Other news stories from 30/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
